Related Experiment Videos
The ABCs of artificial antigen presentation.
Jiyun V Kim1, Jean-Baptiste Latouche, Isabelle Rivière
1Laboratory of Gene Transfer and Gene Expression, Gene Transfer and Somatic Cell Engineering Facility, Department of Medicine and Immunology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
Nature Biotechnology
|April 3, 2004
Summary
Artificial antigen-presenting cells (AAPCs) and cell-free substitutes accelerate therapeutic cellular immunity. These innovative approaches enhance T cell function for adoptive T-cell therapy, impacting future treatments.
Area of Science:
- Immunology
- Cellular Therapy
- Biotechnology
Background:
- Therapeutic cellular immunity is crucial for treating various diseases.
- Current adoptive T-cell therapies often rely on autologous antigen-presenting cells, which can be complex to obtain and utilize.
- There is a need for advanced methods to enhance T cell function ex vivo before therapeutic infusion.
Purpose of the Study:
- To review recent advances in artificial antigen presentation technologies.
- To highlight the potential of artificial antigen-presenting cells (AAPCs) and their cell-free substitutes in T cell expansion and functional enhancement.
- To discuss the impact of these emerging technologies on adoptive T-cell therapy and T cell-mediated immunity research.
Main Methods:
- Review of recent scientific literature and technological developments in artificial antigen presentation.
- Description of various AAPC systems, including fibroblast-based AAPCs and antigen-specific magnetic beads.
- Discussion of novel T-cell costimulatory combinations and the role of interleukin-15 in augmenting T cell potency.
- Exploration of dendritic cell-derived exosomes pulsed with tumor antigen as a therapeutic strategy.
Main Results:
- Emerging technologies demonstrate promise in stimulating T cell expansion and acquiring optimal therapeutic features.
- Fibroblast AAPCs capable of antigen processing and antigen-specific magnetic beads represent significant advancements.
- Novel costimulatory combinations and interleukin-15 show potential for enhancing T cell potency.
- Dendritic cell-derived exosomes offer a safe platform for antigen pulsing in tumor immunotherapy.
Conclusions:
- Artificial antigen presentation technologies, including AAPCs and cell-free substitutes, are poised to significantly impact adoptive T-cell therapy.
- These innovative systems offer alternatives to autologous antigen-presenting cells, potentially simplifying and improving therapeutic strategies.
- Further preclinical and clinical studies are warranted to fully establish the safety and potency of these emerging technologies in T cell-mediated immunity.